

S2 Table. A list of FDA approved multi-target drugs together with their corresponding approval indications and primary therapeutic targets.

<b>Drug Name</b>	<b>Code of ICD class</b>	<b>Disease indication</b>	<b>Target Name</b>
Afatinib	C00-D49	Metastatic non-small cell lung cancer	EGFR; HER2
Bosutinib	C00-D49	Ph+ chronic myelogenous leukemia	ABL; Src
Cabozantinib	C00-D49	Metastatic medullary thyroid cancer	MET; VEGFR2
Dasatinib	C00-D49	Chronic myelogenous and acute lymphoblastic leukemia	ABL; Src
Imatinib	C00-D49	Ph+ chronic myelogenous leukemia	ABL; PDGFR- $\beta$ ; c-Kit
Lapatinib	C00-D49	HER2-positive metastatic breast cancer	EGFR; HER2
Lenvatinib	C00-D49	RAI-refractory differentiated thyroid cancer	VEGFR2; c-Kit
Nintedanib	J00-J99	Idiopathic pulmonary fibrosis	VEGFR2; PDGFR- $\alpha$ ; PDGFR- $\beta$
Palbociclib	C00-D49	ER-positive and HER2-negative breast cancer	CDK4; CDK6
Pazopanib	C00-D49	Renal cell carcinoma and soft tissue sarcoma	VEGFR2; c-Kit; PDGFR- $\beta$
Ponatinib	C00-D49	Chronic myeloid and acute lymphoblastic leukemia	ABL; c-Kit
Regorafenib	C00-D49	Metastatic colorectal cancer and advanced gastrointestinal stromal tumor	VEGFR2; c-Kit
Sorafenib	C00-D49	Renal cell carcinoma and unresectable hepatocellular carcinomas	RET; VEGFR2; PDGFR- $\beta$ ; B-Raf; c-Kit
Sunitinib	C00-D49	Renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumor	VEGFR2; c-Kit; PDGFR- $\beta$
Vandetanib	C00-D49	Medullary thyroid cancer	EGFR; VEGFR2